Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT02551991 · COMPLETED

Trial details

NCT number: NCT02551991
Sponsor: Ipsen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2015-10-19
Primary completion: 2021-02-15
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.